Prognostic value of total metabolic tumour volume and therapy-response assessment by [18F]FDG PET/CT in patients with metastatic melanoma treated with BRAF/MEK inhibitors

ConclusionsBaseline TMTV and metabolic response may be useful prognostic indicators for PFS and OS in patients with advanced melanoma treated with BRAF/MEK inhibitors.Key Points• In a retrospective cohort of 57 metastatic melanoma patients treated with BRAF/MEK inhibitors, a TMTV> 56 cm3 at baseline [18F]FDG PET/CT was significantly correlated with a shorter PFS and OS.• The combined use of baseline TMTV along with PET response during treatment allowed for the identification of three groups of patients with very different median OS.
Source: European Radiology - Category: Radiology Source Type: research